The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
 
Toru Kadono
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Taiho Pharmaceutical; Teijin Pharma
Research Funding - BeiGene (Inst)
 
Hirokazu Shoji
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Natsuko Okita Okita
No Relationships to Disclose
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)